Universal information structure as a tool of long-term follow-up monitoring in allergology

Pediatričeskaâ Farmakologiâ

L.S. Namazova-Baranova¹  A.Yu. Tomilova²  Yu.G. Levina²  A.A. Alekseeva²  K.S. Volkov²  L.R. Selimzyanova²  N.I. Voznesenskaya²  E.V. Antonova²  K.E. Efendieva²  V.I. Smirnov³  E.A. Dobrynina³  E.A. Promyslova³  E.A. Vishneva³ 

[1] Scientific Center of Children’s Health, Moscow, Russian FederationSechenov First Moscow State Medical University, Russian FederationPirogov Russian National Medical Research University, Moscow, Russian Federation;Scientific Center of Children’s Health, Moscow, Russian FederationSechenov First Moscow State Medical University, Russian Federation;Scientific Center of Children’s Health, Moscow, Russian Federation;

关键词: регистр;    система длительного динамического мониторинга;    эффективность;    безопасность;    бронхиальная астма тяжелого персистирующего неконтролируемого течения;    омализумаб;    дети;   

DOI  :  10.15690/pf.v11i5.1167

来源: DOAJ

【 摘 要 】

The article is dedicated to the issues of organization of long-term follow-up monitoring of the patient population in real clinical practice. Every medical intervention is analyzed from the position of positive evidence of its effectiveness, safety and clinical-economic benefits. Although randomized clinical trials (RCTs) are the gold standard of evidence-based medicine, they feature a range of drawbacks; in some cases, such trials are infeasible are extremely complicated to perform due to certain aspects. Along with that, results of RCTs may not completely correlate with clinical practice. Thus, a register – a system of long-term clinical monitoring of a patient population – is a significant source of information on effectiveness and safety of medical interventions. This tool of follow-up observation of a patient’s condition is irreplaceable in medicine, particularly, in allergology both for epidemiological purposes and to assess effectiveness and safety of therapeutic interventions: e.g., use of IgE antibodies – biopharmaceutical omalizumab.Keywords: register, long-term follow-up monitoring system, effectiveness, safety, uncontrolled severe persisting bronchial asthma, omalizumab, children.

【 授权许可】

Unknown